Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06894979 · ClinicalTrials.gov registry record · Phase 1
Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma
A Phase 1 study of Childhood Astrocytoma and Childhood Diffuse Intrinsic Pontine Glioma, sponsored by Children's Oncology Group.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 54
- Enrollment target
- 17
- Study locations
NCT06894979 is a Phase 1 study of Childhood Astrocytoma and Childhood Diffuse Intrinsic Pontine Glioma that is actively recruiting participants, run by Children's Oncology Group. The registered enrollment target is 54 participants. The trial reports 17 study locations across 15 states.
The verdict
NCT06894979, a Phase 1 study of Childhood Astrocytoma and Childhood Diffuse Intrinsic Pontine Glioma, is actively recruiting participants, sponsored by Children's Oncology Group.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 54 participants
- Enrollment target
- 17
- Study locations
Study Summary
This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma. AZD1390 is in a class of medications called kinase inhibitors. It works by blocking the signals that cause cancer cells to multiply. This helps to stop the spread of cancer cells. Radiation therapy uses high energy x-rays, particles, or radioactive seeds to kill cancer cells and shrink tumors. Giving AZD1390 with radiation may be safe, tolerable, and/or effective in treating pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Magnetic Resonance Imaging
- OTHER Survey Administration
- RADIATION Radiation Therapy
- DRUG ATM Kinase Inhibitor AZD1390
Study Locations (17)
California
- Children's Hospital Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
Texas
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center - Houston
- UMC Cancer Center / UMC Health System - Lubbock
Alabama
- Children's Hospital of Alabama - Birmingham
Colorado
- Children's Hospital Colorado - Aurora
District of Columbia
- Children's National Medical Center - Washington D.C.
Georgia
- Children's Healthcare of Atlanta - Arthur M Blank Hospital - Atlanta
Illinois
- Lurie Children's Hospital-Chicago - Chicago
Indiana
- Riley Hospital for Children - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 54 participants |
| Start Date | 2025-06-18 |
| Est. Completion | 2028-03-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06894979
The ClinicalTrials.gov registry entry for NCT06894979 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 54 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Children's Oncology Group, which has 342 total studies on file at ClinicalTrials.gov.
The record links to 5 conditions, with Childhood Astrocytoma appearing as the primary indexed condition, and to 5 interventions - of which Biospecimen Collection is the first listed.
NCT06894979 reports 17 study locations spanning 15 distinct geographic areas - top geographies include California, Texas, Alabama.
Frequently Asked Questions
What is clinical trial NCT06894979 about?
NCT06894979 is a clinical study titled "Testing the Addition of an Anti-Cancer Drug, AZD1390, During Radiation Therapy for Newly Diagnosed High Grade Glioma, Diffuse Midline Glioma, or Diffuse Intrinsic Pontine Glioma". This phase I clinical trial studies the side effects and best dose of AZD1390 and to see how well it works when given together with radiation therapy for the treatment of pediatric patients with high grade glioma, diffuse midline glioma or diffuse intrinsic pontine glioma. AZD1390 is in a class of m...
What is the current status of trial NCT06894979?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 54 participants. The study started on 2025-06-18. Estimated completion is 2028-03-31.
What conditions does trial NCT06894979 study?
This clinical trial studies the following conditions: Childhood Astrocytoma, Childhood Diffuse Intrinsic Pontine Glioma, Childhood Diffuse Midline Glioma, Childhood Glioblastoma, Childhood Malignant Glioma.
What interventions are being tested in trial NCT06894979?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Magnetic Resonance Imaging (PROCEDURE), Survey Administration (OTHER), Radiation Therapy (RADIATION), ATM Kinase Inhibitor AZD1390 (DRUG).
Who is sponsoring clinical trial NCT06894979?
This trial is sponsored by Children's Oncology Group, which has 342 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06894979 being conducted?
This trial has 17 study locations across Alabama, California, Colorado, District of Columbia, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Childhood Astrocytoma
All registered trials for this condition
Childhood Diffuse Intrinsic Pontine Glioma
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.